ZYME
Zymeworks Inc.
Key Financials
Revenue
$106.0M
↑ 38.9%
Net Income
$-81130000
↑ 33.9%
EPS (Diluted)
$-1.08
↑ 33.3%
Operating Income
$-92549000
↑ 32.5%
Total Assets
$346.5M
↓ 25.2%
Shareholders' Equity
$268.5M
↓ 20.7%
Operating Cash Flow
$-33005000.00
↑ 70.0%
Cash & Equivalents
$41.2M
↓ 37.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/15/2026 | View on SEC |
| 3 | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 8-K | 5/14/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| SCHEDULE 13G | 4/15/2026 | View on SEC |
| 4 | 4/10/2026 | View on SEC |
| 4 | 4/10/2026 | View on SEC |
| 3 | 4/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ZYME |
| Company Name | Zymeworks Inc. |
| CIK | 1937653 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 302-274-8744 |